NeuBase Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
NeuBase Therapeutics, Inc. reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of -$429.68 thousand for the 12-month period ending 2019-09-30, per its 10-K filed 2020-12-23.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2020-12-23
- NeuBase Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was -$429.68K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|
| 2019-09-30 | -$429.68K 10-K · filed 2020-12-23 |